Oncological immunotherapies are associated with distinct cardiovascular adverse events, necessitating appropriate baseline cardiovascular assessment and ongoing monitoring to manage complications like heart failure and hypertension.
Answers are grounded in this paper and cite their sources.
Highlights need for cardiac surveillance with HER2 inhibitors; leaves open optimal monitoring in combined immunotherapy regimens.
Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms that block the immune system, and direct destruction of neoplastic cells. Different from chemotherapy or hormonal therapy, its mechanism of action is associated with a different profile of adverse events. HER2 receptor inhibitors may cause symptoms of heart failure, which usually recede, once the treatment has been discontinued. Bevacizumab, an anti-VEGF antibody, induces numerous cardiovascular complications, including arterial hypertension, arterial embolism, haemorrhage and haemoptysis as well as venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Joanna Kufel-Grabowska (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: